Viking Obesity Pill Faces Steep Climb Against Lilly’s Tirzepatide, Analyst Calls Downtrend Reaction ‘Extreme’

Key Takeaways:

• Phase 2 trial participants on oral VK2735 lost up to 12.2 % of body weight in 13 weeks
• The therapy is taken once daily, setting it apart from injectable rivals
• Investors reacted negatively to the data release, driving shares lower
• An analyst labeled the post-data sell-off “extreme”
• VK2735 faces stiff competition from Eli Lilly’s injectable tirzepatide

Lead: Promise Meets Skepticism
Viking Therapeutics thought a double-digit weight-loss figure would buoy enthusiasm for its experimental pill. Instead, the company’s shares slid after it disclosed Phase 2 results for VK2735, a once-daily oral therapy aimed at the booming obesity market. “Investors appear disappointed with Viking Therapeutics Inc.’s data,” the report noted, even as the study delivered what many dieters crave: meaningful weight reduction.

The Trial in Brief
Participants who took VK2735 every day for 13 weeks “demonstrated a mean body-weight reduction of up to 12.2 % from baseline,” according to the company’s data snapshot. That figure, achieved without injections, positions the pill as a potential alternative to existing therapies that require needles.

Market Reaction
Despite the encouraging metric, traders voted with their feet. The stock’s slide was sharp enough for at least one analyst to call the “downtrend reaction ‘extreme.’” The sell-off reflects both short-term profit-taking and questions about how the candidate will fare against entrenched competitors.

Head-to-Head with Lilly
Chief among those rivals is Eli Lilly’s tirzepatide, an injectable whose weight-loss record has already caught clinicians’ and consumers’ attention. The Biztoc brief warned that Viking’s pill “faces a steep climb” against the Lilly blockbuster, underscoring the high bar for any newcomer in the crowded obesity space.

Next Steps
For Viking Therapeutics, the Phase 2 data mark progress, but not a finish line. Larger trials, regulatory hurdles, and head-to-head comparisons still lie ahead. Whether Wall Street’s skepticism proves prescient—or premature—will hinge on the company’s ability to sustain and replicate that 12.2 percent weight-loss figure while convincing investors it can carve out room in a market dominated by big-pharma heavyweights.